- Conditions
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Interventions
- Solriamfetol 150 MG, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 41
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD
- Interventions
- Solriamfetol Dose A, Solriamfetol Dose B, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coral Gables, Florida + 6 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Interventions
- AXS-05, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 61
- States / cities
- Sun City, Arizona • Tucson, Arizona • Chula Vista, California + 55 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis Fatigue
- Interventions
- Solriamfetol, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteoarthritis, Knee
- Interventions
- AXS-02, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 49 more
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Interventions
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- AXS-05, Bupropion SR
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ADHD
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Encino, California • Garden Grove, California • Newport Beach, California + 37 more
- Conditions
- Fibromyalgia
- Interventions
- AXS-14 (esreboxetine)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 18
- States / cities
- Arkansas City, Arkansas • Redlands, California • Sacramento, California + 15 more
- Conditions
- Depression, Major Depressive Disorder
- Interventions
- AXS-05, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more
- Conditions
- Smoking Cessation
- Interventions
- AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • Orlando, Florida + 6 more
- Conditions
- ADHD
- Interventions
- Solriamfetol Dose A, Solriamfetol Dose B, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coral Gables, Florida + 6 more
- Conditions
- Excessive Sleepiness, Shift-work Disorder
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder
- Interventions
- AXS-05 (dextromethorphan-bupropion)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
- Conditions
- Migraine
- Interventions
- AXS-07 (meloxicam-rizatriptan)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 31
- States / cities
- Colton, California • Fullerton, California • La Jolla, California + 28 more
- Conditions
- Treatment Resistant Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 71 more
- Conditions
- ADHD
- Interventions
- Solriamfetol
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Dothan, Alabama • Maitland, Florida
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
- Interventions
- Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
- Drug · Other
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 1,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 2
- States / cities
- Morrisville, North Carolina • Wilmington, North Carolina
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- Excessive Sleepiness, Shift-work Disorder
- Interventions
- Solriamfetol Oral Tablet, Placebo
- Drug
- Lead sponsor
- Charles A. Czeisler, PhD, MD
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Bellflower, California • Encino, California + 35 more
- Conditions
- Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
- Interventions
- AXS-02 (oral zoledronate), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder
- Interventions
- AXS-05, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
- Conditions
- Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more